Atea Pharmaceuticals Inc (NAS:AVIR)
$ 3.71 -0.25 (-6.31%) Market Cap: 312.47 Mil Enterprise Value: -242.18 Mil PE Ratio: 0 PB Ratio: 0.60 GF Score: 43/100

Atea Pharmaceuticals Inc at JPMorgan Healthcare Conference (Virtual) Transcript

Jan 10, 2022 / 01:15PM GMT
Release Date Price: $7.68 (+0.52%)
Eric William Joseph
JPMorgan Chase & Co, Research Division - VP & Senior Analyst

Good morning, and welcome to the 40th Annual JPMorgan Healthcare Conference. I'm Eric Joseph, senior biotech analyst at the firm. Our next presenting company this morning is Atea Pharmaceuticals and to talk to us a little bit about the company is CEO, JP Sommadossi. Quick programming note, there is a Q&A session following the presentation. Simply click the ask a question button to submit and I'll work those in where appropriate.

With that, JP, thanks for joining us. Take it away.

Jean;Pierre Sommadossi
Atea Pharmaceuticals, Inc. - Founder, Chairman, CEO & President

Thank you, Eric, and thank you for the opportunity to present today at your conference. So before we begin, this is our forward-looking statement and further information can be found in our most recent filings.

Since the founding of Atea, as we discover breakthrough drugs against RNA viruses. Our platform of purine nucleotide prodrugs and bemnifosbuvir, which is the

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot